Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription Articles published in Urol Int Retrieve available abstracts of 45 articles: HTML format

Single Articles

August 2026
1. BICAKLIOGLU F, Akyol Y, Mert MS, Eryildirim B, et al
   Gleason 6 Prostate Cancer: Predictors of Upgrading in a High-Volume Turkish Tertiary Center.
   Urol Int. 2026 Aug 28:1. doi: 10.1159.
   PubMed     Abstract available
   
   
   
2. ALBAYRAK E, Hizarci Bal R, Altan M, Yazici S, et al
   Incidence, Clinicopathological Features, and Survival Impact of Incidental Prostate Cancer in Radical Cystoprostatectomy: A Single-Center Analysis.
   Urol Int. 2026 Aug 20:1-11. doi: 10.1159/000553544.
   PubMed     Abstract available
   
   
   
3. STEENBOCK O, Rieger C, Heidenreich J, Paffenholz P, et al
   How Often are druggable mutations detectable in Metastatic Castration Resistant Prostate Cancer?
   Urol Int. 2026 Aug 13:1. doi: 10.1159.
   PubMed     Abstract available
   
   
   July 2026
4. MELCHIOR F, Koett M, Aigner G, Schroffenegger J, et al
   Real-World Use of Prolaris(R) to Guide Treatment Decisions in Localized Prostate Cancer Eligible for Active Surveillance.
   Urol Int. 2026 Jul 17:1-14. doi: 10.1159/000553659.
   PubMed     Abstract available
   
   
   June 2026
5. SHEN B, Wang F
   Precision Nodal Staging in Intermediate-Risk Prostate Cancer: A Narrative Review of Molecular Imaging.
   Urol Int. 2026 Jun 12:1-19. doi: 10.1159/000552660.
   PubMed     Abstract available
   
   
   
6. BEHNEL N, Engelage L, Lumiani A, Buchner A, et al
   Transition Zone PSA Density Does Not Improve Detection of Clinically Significant Prostate Cancer Over Whole-Gland PSAD: A Volume-Stratified Analysis in 3,958 Patients.
   Urol Int. 2026 Jun 4:1-15. doi: 10.1159/000552900.
   PubMed     Abstract available
   
   
   
7. ALBARGHOUTH MH, Leeder M, Leucht K, Seifert P, et al
   Diagnostic Value of PSMA-PET/CT for the Detection of Pelvic Lymph Node Metastasis in Intermediate and High-Risk Prostate Cancer.
   Urol Int. 2026 Jun 4:1-14. doi: 10.1159/000552672.
   PubMed     Abstract available
   
   
   April 2026
8. SCHOSTAK M, Peklo E, Peters I, Machtens S, et al
   Parameters predicting Recurrence after Focal Therapy for Prostate Cancer: Insights from a Multicenter Surveillance Database.
   Urol Int. 2026 Apr 2:1-20. doi: 10.1159/000551632.
   PubMed     Abstract available
   
   
   February 2026
9. DONCK E, Fede Spicchiale C, Yang T, Bou Kheir G, et al
   Pelvic lymph node dissection during radical prostatectomy for prostate cancer: harms versus benefits.
   Urol Int. 2026 Feb 2:1-21. doi: 10.1159/000550027.
   PubMed     Abstract available
   
   
   January 2026
10. AYDOGDU C, Urban F, Berg E, Gotz M, et al
    Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study.
    Urol Int. 2026 Jan 19:1-20. doi: 10.1159/000550580.
    PubMed     Abstract available
    
    
    
11. POLAT H, Sungur U, Eksi M, Guner E, et al
    The Relationship of Chronic Inflammation in Prostate Biopsies with International Society of Urological Pathology Score Upgrade after Radical Prostatectomy.
    Urol Int. 2026;110:55-61.
    PubMed     Abstract available
    
    
    
12. ELLEISY M, Resch I, Yurdakul O, Hubner NA, et al
    Acute Kidney Injury in a Cancer Patient Exposed to Relugolix and Abiraterone.
    Urol Int. 2026;110:198-201.
    PubMed     Abstract available
    
    
    November 2025
13. GORGEL SN, Akin Y, Yorulmaz EM, Donmez K, et al
    Predictive Value of Node-RADS for Lymph Node Involvement in Prostate Cancer: A Matched Cohort Study.
    Urol Int. 2025 Nov 3:1-19. doi: 10.1159/000549303.
    PubMed     Abstract available
    
    
    October 2025
14. RISCH J, Hugelmann K, Buck L, von Knobloch HC, et al
    Readability of Prostate Cancer Patient Education Materials: A Comprehensive Assessment Using Readability Metrics.
    Urol Int. 2025 Oct 9:1-15. doi: 10.1159/000548884.
    PubMed     Abstract available
    
    
    August 2025
15. LUO H, Liao G, Liu Y
    Efficacy of Neoadjuvant Hormone Therapy Combined with Radical Prostatectomy in Improving Oncological Outcomes for Patients with cT3 Prostate Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2025 Aug 13:1-37. doi: 10.1159/000547875.
    PubMed     Abstract available
    
    
    July 2025
16. PHILIPPOU C, Gloger S, Ubrig B, Bitterlich N, et al
    Estimating Bone Metastasis Risk in Prostate Cancer: A Three-Parameter Model using BSP, ISUP Grading, and Tumor Progression.
    Urol Int. 2025 Jul 25:1-34. doi: 10.1159/000547556.
    PubMed     Abstract available
    
    
    June 2025
17. PINA-VAZ T, Costa Silva A, Costa G, Goncalves M, et al
    Sexually Transmitted Infections in Prostate Cancer: A Prospective Multicenter Analysis.
    Urol Int. 2025 Jun 21:1-13. doi: 10.1159/000545208.
    PubMed     Abstract available
    
    
    May 2025
18. NIRAZUKA A, Nakayama A, Inoue M, Tsujioka H, et al
    Impact of an Early Prostate-Specific Antigen Response on Biochemical Progression During Upfront Androgen Receptor Signal Inhibitor Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    Urol Int. 2025 May 22:1-18. doi: 10.1159/000546327.
    PubMed     Abstract available
    
    
    April 2025
19. BORKOWETZ A, Wullich B, Saar M, Schmidt-Hegemann N, et al
    Treatment strategies in oligo-metastatic prostate cancer - a nation-wide survey.
    Urol Int. 2025 Apr 14:1-20. doi: 10.1159/000545630.
    PubMed     Abstract available
    
    
    January 2025
20. FIORELLO N, Zucchi A, Gregori F, Romei G, et al
    Urinary Leakage after Robot-Assisted Radical Prostatectomy: Is Always Predictive of Functional Results?
    Urol Int. 2025;109:68-73.
    PubMed     Abstract available
    
    
    
21. ELLEISY M, Drager DL, Zettl H, Hakenberg OW, et al
    COVID-19 Pandemic Impact on Uro-Oncological Disease Outcomes at a German Referral Center.
    Urol Int. 2025;109:135-145.
    PubMed     Abstract available
    
    
    
22. SPACHMANN PJ, Witt D, Breyer J, Denzinger S, et al
    Antibiotic Prophylaxis of Transrectal Biopsy of the Prostate: A Plea for Fosfomycin.
    Urol Int. 2025;109:146-150.
    PubMed     Abstract available
    
    
    
23. ELLEISY M, Zettl H, Drager DL, Hakenberg OW, et al
    The Impact of Diabetes and Antidiabetics on Uro-Oncological Disease Outcomes: A Single-Center Experience.
    Urol Int. 2025;109:361-371.
    PubMed     Abstract available
    
    
    
24. BAHLBURG H, Bahlburg H, Rausch P, Silberg M, et al
    Stage Migration in Urological Cancers in Germany during the COVID-19 Pandemic: Fact or Fiction?
    Urol Int. 2025;109:501-507.
    PubMed     Abstract available
    
    
    
25. SCHMITZ-DRAGER BJ, Schmitz-Drager BJ, Bismarck E, Ebert T, et al
    Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN).
    Urol Int. 2025;109:519-527.
    PubMed     Abstract available
    
    
    October 2024
26. JI G, Liu F, Chen Z, Peng J, et al
    Correlation of magnetic resonance imaging and computed tomography with biological factor expression and lymph node metastasis in aggressive prostate cancer.
    Urol Int. 2024 Oct 25:1-8. doi: 10.1159/000541953.
    PubMed     Abstract available
    
    
    
27. YU J, Zhou K, Wang J, Mao L, et al
    Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration?resistant prostate cancer: a single-center, open-label study.
    Urol Int. 2024 Oct 15:1-13. doi: 10.1159/000541929.
    PubMed     Abstract available
    
    
    
28. OPPOLZER IA, Schnabel MJ, Hammer S, Zilles H, et al
    Impact of SARS-CoV-2-Pandemic on diagnosis of prostate cancer.
    Urol Int. 2024 Oct 3:1-15. doi: 10.1159/000541753.
    PubMed     Abstract available
    
    
    September 2024
29. BULBUL O, Nak D, Goksel S
    Prediction of lesion-based treatment response after two cycles of Lu-177 PSMA treatment in metastatic castration-resistant prostate cancer using machine learning.
    Urol Int. 2024 Sep 30:1-12. doi: 10.1159/000541628.
    PubMed     Abstract available
    
    
    August 2024
30. OBERNEDER M, Henzler T, Kriegmair M, Vag T, et al
    Prediction of clinically significant prostate cancer using multi parametric MRI, biparametric MRI and clinical parameters.
    Urol Int. 2024 Aug 31. doi: 10.1159/000541152.
    PubMed     Abstract available
    
    
    May 2024
31. GLOGER S, Paulics L, Philippou C, Philippou S, et al
    Perioperative rates of incidental prostate cancer after aquablation and holmium laser enucleation of the prostate (HoLEP).
    Urol Int. 2024 May 27. doi: 10.1159/000539014.
    PubMed     Abstract available
    
    
    March 2024
32. SIMSEK A, Celen S, Duran MB, Kucuker K, et al
    THE DIAGNOSTIC ACCURACY OF A COMBINATION OF PREOPERATIVE 68-Ga PSMA PET/CT AND MULTIPARAMETRIC MRI IN LOCALIZED PROSTATE CANCER.
    Urol Int. 2024 Mar 13. doi: 10.1159/000538061.
    PubMed     Abstract available
    
    
    
33. HU S, Xiong X, Qiu S, Li J, et al
    Comparing efficacies of different exercises on androgen deprivation therapy adverse effects in prostate cancer patients: a network meta-analysis.
    Urol Int. 2024 Mar 2. doi: 10.1159/000538114.
    PubMed     Abstract available
    
    
    January 2024
34. RIEDEL A, Michael M, Grunberg J, Mehralivand S, et al
    The role of multiparametric MRI (mpMRI) in the prediction of adverse prostate cancer pathology in radical prostatectomy specimen.
    Urol Int. 2024 Jan 19. doi: 10.1159/000536256.
    PubMed     Abstract available
    
    
    
35. WU S, Feldman AS, Lin SX, Kim MM, et al
    Estimated Prostate Volume by Semiautomatic Segmentation of MRI Is More Accurately Correlated with Radical Prostatectomy Specimen Weight than the Volume Calculated by Ellipsoid Formula.
    Urol Int. 2024;108:35-41.
    PubMed     Abstract available
    
    
    
36. SIGG S, Arnold W, Grossmann NC, Baumeister P, et al
    Why Do Men Reject Adjuvant Radiotherapy following Radical Prostatectomy? A Systematic Survey.
    Urol Int. 2024;108:211-218.
    PubMed     Abstract available
    
    
    
37. FARZAT M, Wagenlehner FM
    How Might the Number of Lymph Nodes Removed during RARP Impact the Postoperative Outcomes?
    Urol Int. 2024;108:175-182.
    PubMed     Abstract available
    
    
    
38. FERRANDINO MN, Espino G, Young M, Bodden E, et al
    Initial Experience with an Absorbable Urologic Scaffold to Mitigate Early Urinary Incontinence following Radical Prostatectomy: A Report of 2 Cases.
    Urol Int. 2024;108:574-577.
    PubMed     Abstract available
    
    
    November 2023
39. CANKAYA S, Caylan AE, Aydin F, Ucar M, et al
    Correlation between prostate cancer positive cores and 68Ga-PSMA distribution in prostate gland.
    Urol Int. 2023 Nov 28. doi: 10.1159/000535466.
    PubMed     Abstract available
    
    
    
40. CUI Y, Zhao J, Sun Y
    The Value of the Prostate Health Index and Derived Indexes in the Diagnosis of Prostate Cancer with PI-RADS-3 Lesions.
    Urol Int. 2023 Nov 27:1-6. doi: 10.1159/000534597.
    PubMed     Abstract available
    
    
    
41. SENEL S, Koudonas A, Uzun E, Ceviz K, et al
    The Value of Prostate-Specific Antigen Density in Combination with Lesion Diameter for the Accuracy of Prostate Cancer Prediction in Prostate Imaging-Reporting and Data System 3 Prostate Lesions.
    Urol Int. 2023 Nov 20:1-6. doi: 10.1159/000534805.
    PubMed     Abstract available
    
    
    
42. SIKIC D, Fiebig C, Wullich B, Wolff I, et al
    Patient Benefits of Radical Prostatectomy in Certified Prostate Cancer Centers: Comparative Results from the Multicenter IMPROVE Study.
    Urol Int. 2023 Nov 6:1-10. doi: 10.1159/000534486.
    PubMed     Abstract available
    
    
    January 2023
43. SHEN C, Zhang DL, Cheng XL, Zhang WC, et al
    Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
    Urol Int. 2023;107:841-847.
    PubMed     Abstract available
    
    
    
44. SCARCIA M, Moretto S, Zazzara M, Alba S, et al
    Robot-Assisted Extraperitoneal Radical Prostatectomy for Giant Multilocular Prostatic Cystadenoma: A Case Report and Literature Review.
    Urol Int. 2023;107.
    PubMed     Abstract available
    
    
    
45. STOLZENBACH LF, Fankhauser CD, Mattei A, Wurnschimmel C, et al
    Solitary Fibrous Tumor of the Prostate Treated with Frozen-Section Supported Robot-Assisted Nerve-Sparing Radical Prostatectomy.
    Urol Int. 2023;107.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum